ArriVent BioPharma, Inc. AVBP Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$145.24M-14.0% | -$166.31M-107% | -$151.4M-86.8% | -$136.98M-82.9% | -$127.46M-70.9% | ||
| -$2.83M— | -$3.03M— | —— | —— | —— | ||
| $15.73M+224% | $12.52M+290% | $10.25M+298% | $7.4M+284% | $4.85M+258% | ||
| -$134.47M-12.4% | -$160.59M-129% | -$146.08M-112% | -$126.63M-86.0% | -$119.59M-108% | ||
| -$104.47M+2.8% | -$71.23M+63.0% | -$48.15M— | -$45.5M— | -$107.53M— | ||
| $251.18M+3,159% | $203.06M+8.8% | $168.39M— | $82.46M— | $7.71M— | ||
| $12.24M— | -$28.75M— | -$170.18M— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does ArriVent BioPharma, Inc.'s cash flow data come from?
- Every line is extracted from ArriVent BioPharma, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.